Pre‐Diagnostic Circulating Glycerolipids Are Enriched in Men Who Develop Advanced Prostate Cancer: A Nested Case–Control Study

Few studies with pre‐diagnostic samples have estimated associations between circulating metabolites and risk of advanced prostate cancer. We performed untargeted metabolomic profiling of pre‐diagnostic blood samples from 212 advanced prostate cancer cases (stage ≥ T3b or lethal during follow‐up) and 212 matched controls from the Health Professionals Follow‐up Study. 243 metabolites were assayed using liquid chromatography–tandem mass spectrometry (Broad Institute) and met quality control standards. We used multivariable conditional logistic regression to generate odds ratios (OR) and 95% confidence intervals (95% CI) for associations between individual metabolites and risk of advanced prostate cancer, and conducted metabolite set enrichment tests to identify metabolite classes enriched in advanced prostate cancer. Subgroup analyses were conducted by body mass index (BMI) and time between blood draw and diagnosis. Levels of 16 lipid metabolites were nominally associated with advanced prostate cancer at p < 0.05, though none were statistically significant after multiple testing correction. The strongest signals were for C56:1 triacylglycerol (TAG; OR: 1.34, 95% CI: 1.07–1.67) and C38:4 diacylglycerol (DAG; OR: 1.27, 95% CI: 1.04–1.55). Enrichment analyses revealed six metabolite classes associated with advanced prostate cancer after multiple testing adjustment, the top four of which were DAGs and TAGs: DAGs overall ( p = 3.4E−07), unsaturated DAGs ( p = 5.9E−07), unsaturated TAGs ( p = 2.3E−06), and TAGs overall ( p = 2.4E−06). 48 metabolites were nominally associated with advanced prostate cancer among individuals with BMI < 25 kg/m 2 ; only three demonstrated nominal associations in individuals with BMI ≥ 25 kg/m 2 . These findings suggest a possible relationship between circulating pre‐diagnostic lipid levels and aggressive prostate cancer risk, particularly in lean individuals.

Authors

Institutions

Publication Details

Journal
International Journal of Cancer
Published
2026-11-21
DOI
https://doi.org/10.1002/ijc.70830
Primary Topic
Metabolomics and Mass Spectrometry Studies
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Pre‐Diagnostic Circulating Glycerolipids Are Enriched in Men Who Develop Advanced Prostate Cancer: A Nested Case–Control Study

Matthew G. Vander Heiden, Harriett Fuller, Kathryn M. Wilson, Rebecca E. Graff et al.
1 links
International Journal of Cancer
Metabolomics and Mass Spectrometry Studies
article

Pre‐Diagnostic Circulating Glycerolipids Are Enriched in Men Who Develop Advanced Prostate Cancer: A Nested Case–Control Study

Matthew G. Vander Heiden, Harriett Fuller, Kathryn M. Wilson, Rebecca E. Graff, Lorelei Ann Mucci, Philip W. Kantoff, Clary B. Clish, Burcu F. Darst, Barbra A. Dickerman, June M. Chan, Ericka M. Ebot, Xiaoshuang Feng
article en

Abstract

Few studies with pre‐diagnostic samples have estimated associations between circulating metabolites and risk of advanced prostate cancer. We performed untargeted metabolomic profiling of pre‐diagnostic blood samples from 212 advanced prostate cancer cases (stage ≥ T3b or lethal during follow‐up) and 212 matched controls from the Health Professionals Follow‐up Study. 243 metabolites were assayed using liquid chromatography–tandem mass spectrometry (Broad Institute) and met quality control standards. We used multivariable conditional logistic regression to generate odds ratios (OR) and 95% confidence intervals (95% CI) for associations between individual metabolites and risk of advanced prostate cancer, and conducted metabolite set enrichment tests to identify metabolite classes enriched in advanced prostate cancer. Subgroup analyses were conducted by body mass index (BMI) and time between blood draw and diagnosis. Levels of 16 lipid metabolites were nominally associated with advanced prostate cancer at p < 0.05, though none were statistically significant after multiple testing correction. The strongest signals were for C56:1 triacylglycerol (TAG; OR: 1.34, 95% CI: 1.07–1.67) and C38:4 diacylglycerol (DAG; OR: 1.27, 95% CI: 1.04–1.55). Enrichment analyses revealed six metabolite classes associated with advanced prostate cancer after multiple testing adjustment, the top four of which were DAGs and TAGs: DAGs overall ( p = 3.4E−07), unsaturated DAGs ( p = 5.9E−07), unsaturated TAGs ( p = 2.3E−06), and TAGs overall ( p = 2.4E−06). 48 metabolites were nominally associated with advanced prostate cancer among individuals with BMI < 25 kg/m 2 ; only three demonstrated nominal associations in individuals with BMI ≥ 25 kg/m 2 . These findings suggest a possible relationship between circulating pre‐diagnostic lipid levels and aggressive prostate cancer risk, particularly in lean individuals.

International Journal of Cancer
Broad Institute (US), American Cancer Society (US), Harvard University (US), University of California, San Francisco (US), Fred Hutch Cancer Center (US), Dana-Farber Cancer Institute (US), Centre international de recherche sur le cancer (FR), Koch Institute for Integrative Cancer Research At MIT (US), Massachusetts Institute of Technology (US)
Prostate Cancer Foundation, World Health Organization, Dana-Farber/Harvard Cancer Center, National Institutes of Health, National Cancer Institute
Good health and well-being
Metabolomics and Mass Spectrometry Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon